Quick Answer
VACCINEX, INC. reported Long-Term Debt of $0.00 for fiscal year 2024.
VACCINEX, INC. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $0.00 | -100.0% |
| 2023 | $26.0K | -74.3% |
| 2022 | $101.0K | -42.3% |
| 2021 | $175.0K | -84.6% |
| 2020 | $1.13M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | $6.0K | -92.7% | -76.9% |
| December 31, 2023 | $26.0K | -74.3% | -40.9% |
| September 30, 2023 | $44.0K | -63.0% | -30.2% |
| June 30, 2023 | $63.0K | -54.3% | -23.2% |
| March 31, 2023 | $82.0K | -47.4% | -18.8% |
| December 31, 2022 | $101.0K | -42.3% | -15.1% |
| September 30, 2022 | $119.0K | -89.5% | -13.8% |
| June 30, 2022 | $138.0K | -87.8% | -11.5% |
- VACCINEX, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2020–2024 period, VACCINEX, INC.’s long-term debt has declined by 100.0% (from $1.13 million to $0.00).
- The most recent figure is from VACCINEX, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: